Eli Lilly to Invest Over $1 Billion in India For New Manufacturing Facilities

Eli Lilly and Co. said on Monday it will invest more than $1 billion over the next few years in new contract manufacturing facilities in India to expand its production and supply capabilities. The US pharmaceutical major currently operates a commercial site in Gurugram and specialised sites in Bengaluru and Hyderabad.

In September, Eli Lilly received approval for its weight-loss and diabetes drug Mounjaro from the Central Drugs Standard Control Organisation. Although the company did not specify products linked to the new investment, industry sources expect it to outsource manufacturing of Mounjaro to Indian contract manufacturers. Mounjaro, a glucagon-like peptide-1 drug with dual action, has been a blockbuster globally.

Eli Lilly said the investment will strengthen its ability to deliver medicines at scale while maintaining quality standards. The company will also set up a new manufacturing and quality centre in Hyderabad to oversee its contract manufacturing network in India.

Recruitment for the new units will begin immediately, with openings for engineers, chemists, analytical scientists, quality professionals, and managers.

Eli Lilly said the investment reflects its plan to leverage India’s skilled talent base to support global growth. Since 2020, the company has committed over $55 billion to build, expand, and acquire manufacturing facilities worldwide.